TGF-β1–induced expression of human Mdm2 correlates with late-stage metastatic breast cancer
Open accessAbstract
The E3 ubiquitin ligase human murine double minute (HDM2) is overexpressed in 40%-80% of late-stage metastatic cancers in the absence of gene amplification. Hdm2 regulates p53 stability via ubiquitination and has also been implicated in altering the sensitivity of cells to TGF-beta1. Whether TGF-beta1 signaling induces Hdm2 expression leading to HDM2-mediated destabilization of p53 has not been investigated. In this study, we report that TGF-beta1-activated SMA- and MAD3 (Smad3/4) transcription factors specifically bound to the second promoter region of HDM2, leading to increased HDM2 protein expression and destabilization of p53 in human cancer cell lines. Additionally, TGF-beta1 expression led to Smad3 activation and murine double minute 2 (Mdm2) expression in murine mammary epithelial cells during epithelial-to-mesenchymal transition (EMT). Furthermore, histological analyses of human breast cancer samples demonstrated that approximately 65% of late-stage carcinomas were positive for activated Smad3 and HDM2, indicating a strong correlation between TGF-beta1-mediated induction of HDM2 and late-stage tumor progression. Identification of Hdm2 as a downstream target of TGF-beta1 represents a critical prosurvival mechanism in cancer progression and provides another point for therapeutic intervention in late-stage cancer.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
High Mdm2 levels correlate with a higher incidence of metastasis in vivo.
“Moreover, evidence suggests that high Mdm2 levels correlate with a higher incidence of metastasis in vivo (6, 8, 9).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [8]
Some studies indicate that Mdm2 overexpression or gene amplification is associated with worse prognosis in breast cancer.
“In breast cancers, studies have shown Mdm2 gene amplifications range from 10–60% with some studies indicating a worse prognosis with overexpression of Mdm2 or gene amplification (6, 8).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [8]
Mdm2 gene amplifications are found in 10-60% of breast cancers.
“In breast cancers, studies have shown Mdm2 gene amplifications range from 10–60% with some studies indicating a worse prognosis with overexpression of Mdm2 or gene amplification (6, 8).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 60 · Cited by 133
Research works printed but not linked: 1
- Criswell TL, et al. Delayed activation of IGF- 1R/Src/MAPK/Egr-1 signaling regulates clus- terin expression, a pro-survival factor. J Biol Chem. 2005;280(14):14212-14221.
- Authors
- Araki, S., Eitel, J. A., Batuello, C. N., Bijangi-Vishehsaraei, K., Xie, X.-J., Danielpour, D., Pollok, K. E., Boothman, D. A., & Mayo, L. D.
- Affiliations
- Harold C. Simmons Comprehensive Cancer Center (US)
- Indiana University Indianapolis (US)
- Case Comprehensive Cancer Center (US)
- Indiana University – Purdue University Indianapolis (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2010-01-04
- Volume
- 120
- Issue
- 1
- Pages
- 290-302
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2798681
- OpenAlex
- W2124433932
- Cited by
- 133
- References
- 60
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 6 · 2023: 5 · 2022: 3 · 2021: 7 · 2020: 4 · 2019: 11 · 2018: 4 · 2017: 8 · 2016: 2 · 2015: 5 · 2014: 16 · 2013: 12 · 2012: 26
- FWCI
- 6.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Energy (DE-FG02-09ER64789, DE‐FG02‐)
- National Institutes of Health (NIH-R01)
- National Cancer Institute (R01CA139217, P30CA08709, R01CA109262, R01CA102792, P30CA142543)
- National Institute of Allergy and Infectious Diseases (U19AI067773)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Kruppel-like factors research
- Keywords
- TGF-β1, MDM2, Smad3, SMAD4, breast cancer metastasis, epithelial-mesenchymal transition, transcriptional regulation, tumor progression, E3 ubiquitin ligase
- MeSH terms
- Breast Neoplasms, Female, Humans, Imidazoles, Neoplasm Staging, Piperazines, Promoter Regions, Genetic, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Apoptosis, HCT116 Cells, Proto-Oncogene Proteins c-mdm2, Smad3 Protein, Transforming Growth Factor beta1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review